Matthew John Baggott is an American neuroscientist who studies entactogens, hallucinogens, and other psychoactive drugs.
[9][8][10] Baggott is co-founder and CEO of Tactogen, a public benefit corporation started in 2020 that is developing novel MDMA-like drugs as medicines.
[12][7][8][13] Baggott was involved in the first Food and Drug Administration (FDA)-approved clinical studies of MDMA and MDA.
[1][7][8] In January 14, 2022, the Drug Enforcement Agency (DEA) proposed moving five unscheduled and relatively obscure psychedelic tryptamines, including 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT, into the Schedule I controlled substances category in the United States.
[15][16] Baggott and Tactogen, as well as a large number of other individuals and organizations, publicly challenged and opposed the proposal.